GenSight Biologics S.A.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Latest news
All GSGTF news ›Gensight Biologics Announces Executive Changes
GenSight Biologics announced the strategic expansion of its Regulatory Affairs & Quality department with two senior appointments following recent regulatory milestones. The company named Fang Li,... GenSight Biologics announced the…
GenSight Biologics Closes EUR1.7 Million Fundraising
GenSight Biologics secured 1.7 million euros from a recently closed fundraising subscribed by three of its shareholders, according to a Wednesday release. The French clinical-stage biotechnology... Biotechnology & Medical Research GenSight…
GenSight Biologics: Cash Runway Secured Through Year-End 2026
The biopharmaceutical company reached a pivotal milestone in 2025, marked by significant regulatory progress that establishes a solid foundation for 2026. Against this backdrop, the company estimates... In parallel, preparatory work for…
GenSight Biologics S.A.: Relative Strength Chart - Stock Euronext Paris
Compare GenSight Biologics S.A. with the company of your choice via a Relative Strength chart. Real-time SIGHT price, Euronext Paris stock exchange Relative Strength Chart GenSight Biologics S.A. Biotechnology & Medical Research All…
GenSight Biologics S.A. Stock (SIGHT) - Quote Euronext Paris
GenSight Biologics S.A. specializes in the research and development of gene therapies for the treatment of mitochondrial diseases and eye neurodegeneratives. At the end of 2025, the company had a portfolio of 2 products, including 1 in…
GenSight Biologics S.A. Auditor Raises 'Going Concern' Doubt
GenSight Biologics S.A. filed its Annual on Apr 15, 2026 for the period ending Dec 31, 2025. In this report its auditor, BECOUZE,Deloitte & Associés, gave an unqualified opinion expressing doubt that... Biotechnology & Medical Research…
GenSight Biologics S.A. Provides Updates About GS010/LUMEVOQ Early Access Programs And The Ongoing REVISE Study
GenSight Biologics S.A. provided updates on the GS010/LUMEVOQ early access programs currently underway and the ongoing dose-ranging study REVISE. GS010/LUMEVOQ is the Company?s candidate gene therapy... provided updates on the…
GenSight Biologics Announces the Closing of its €1.0 Million Fundraising Supported by Existing Shareholders
NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES OF AMERICA, CANADA, AUSTRALIA, JAPAN AND SOUTH AFRICA Published on 10/16/2026 at 12:00 pm EDT The Fundraising resulted in the issuance of: The Offered Investor Warrants and…
GenSight Biologics announces the results of its extraordinary general meeting of January 28, 2026
GenSight Biologics SA: * GenSight Biologics announces the results of its extraordinary general meeting of January 28, 2026 ... Biotechnology & Medical Research GenSight Biologics announces the results of its extraordinary general meeting…
Gensight Biologics S.A. Provides Consolidated Earnings Guidance for the Full Year Ended December 31, 2025
GenSight Biologics S.A. provided consolidated earnings guidance for the full year ended December 31, 2025. For the year, the company expected revenues of EUR 1,000; total operating income of EUR... Published on 03/27/2026 at 07:06 am EDT…
From articles in the 4Search news index.
In the news
Mentioned with
People in the coverage
Most coverage from
-
marketscreener.com10
-
scanx.trade1
Finance and business coverage in the 4Conservative news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 11 articles, not a forecast.